Amyris IPO
Amyris is a synthetic biology company that engineers microorganisms to produce sustainable ingredients for health, beauty, and flavor markets. The company has attracted investor attention for its platform approach to biomanufacturing and partnerships with major consumer brands, though it has faced challenges with profitability and execution.
What We Know
Amyris went public in September 2010, raising approximately $85 million in its IPO at $16 per share. The company trades on NASDAQ under the ticker symbol AMRS and has been public for over 13 years. The stock has experienced extreme volatility since its IPO, reaching highs above $60 during the 2021 biotech boom but also trading below $1 at various points due to execution challenges and market concerns about the company's path to profitability. Amyris has pivoted its strategy multiple times, focusing on different end markets and business models while building out its synthetic biology platform.
Frequently Asked Questions
Has Amyris had an IPO?
Yes, Amyris completed its IPO in September 2010 and has been publicly traded for over 13 years. The company trades on NASDAQ under the ticker AMRS.
When is the Amyris IPO date?
Amyris already completed its IPO in September 2010. The company has been publicly traded on NASDAQ for more than a decade.
How can I buy Amyris stock?
You can buy Amyris stock through any brokerage account as it trades publicly on NASDAQ under the ticker symbol AMRS. The stock is available for purchase during regular market hours and after-hours trading.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts